Skip Navigation


Annals of Oncology Advance Access originally published online on September 9, 2007
Annals of Oncology 2007 18(10):1591-1593; doi:10.1093/annonc/mdm342
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/10/1591    most recent
mdm342v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Carella, A. M.
Right arrow Articles by Bregni, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carella, A. M.
Right arrow Articles by Bregni, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

editorial

Current role of allogeneic stem cell transplantation in breast cancer

A. M. Carella1,* and M. Bregni2

1 Division of Hematology I, Azienda Ospedaliera Universitaria San Martino, Genova
2 Strategic Program in Oncology, Istituto San Raffaele, Milano, Italy

* (E-mail: angelomichele.carella@hsanmartino.it)

The first 150 words of the full text of this article appear below.

The majority of patients with metastatic breast cancer will relapse and will die of their disease. Allogeneic stem cell transplantation (AlloSCT) with myeloablative conditioning regimens may provide cytoreduction and eradication of disease with two advantages: a cancer free-graft and an immune-mediated graft-versus-tumor (GVT) effect mediated by the donor's immune cells. The first report of an AlloSCT in solid tumors has been published in 1996 [1]. Since then, several small series have been published, especially in renal cell and breast cancer [2, 3–11]. With reduced-intensity conditioning regimens (RICT), the goal of transplantation is the achievement of a full donor engraftment and the induction of a GVT effect, rather than chemotherapy-related cytoreduction. Clinical responses suggestive of a GVT effects have been reported, and more than 1000 patients with refractory and advanced solid tumors, to date, have undergone RICT in EBMT centers.

graft-versus-breast cancer effect
In 1996, Eibl et . . . [Full Text of this Article]

reduced-intensity conditioning regimens for AlloSCT
will allografting have a place in the busy therapeutic armamentarium of breast cancer?

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
L. Hambach, M. Vermeij, A. Buser, Z. Aghai, T. van der Kwast, and E. Goulmy
Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors
Blood, September 1, 2008; 112(5): 1844 - 1852.
[Abstract] [Full Text] [PDF]